Biogen (BIIB) : The money flow analysis of Biogen (BIIB) indicates a $43.04 million of outflow was on downticks, whereas, the investors on Thursday gobbled up stocks worth $47.06 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.09 and so was the total money flow at $4.02 million. The bulls lapped up $3.15 million worth of block trades on upticks. The money flow was $3.15 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Biogen (BIIB), pushing it down by 0% for the day. The stock slid $0.01 and traded at $251.18 during the day. Nonetheless, the stock is -0.05% over the previous weeks close.
The stock has recorded a 20-day Moving Average of 5.01% and the 50-Day Moving Average is 1.62%. Shares have dropped -35.45% from its 1 Year high price. On Jul 21, 2015, the shares registered one year high at $412.24 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $253.82 and the 200 Day Moving Average price is recorded at $264.68.
Biogen (NASDAQ:BIIB): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $253.30 and $250.02 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $253.80. The buying momentum continued till the end and the stock did not give up its gains. It closed at $252.87, notching a gain of 0.67% for the day. The total traded volume was 1,295,371 . The stock had closed at $251.19 on the previous day.
In an insider trading activity, The Securities and Exchange Commission has divulged that Koppel Adam, officer (EVP, Strategy and Bus. Dev.) of Biogen Inc., had unloaded 555 shares at an average price of $290 in a transaction dated on June 6, 2016. The total value of the transaction was worth $160,950.
Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.